Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512499 | 0.82 | HDAC6 (0.44) | HDAC6HDAC1LTA4H | |
| Hydrochloric Acid SCHEMBL6150951 | 0.81 | HDAC6 (0.43) | HDAC6HDAC1LTA4H | |
| SCHEMBL2182600 | 0.78 | HDAC6 (0.42) | HDAC6HDAC1LTA4H | |
| SCHEMBL27626433 | 0.78 | HDAC6 (0.45) | HDAC6HDAC1LTA4H | |
| SCHEMBL5360602 | 0.77 | HDAC6 (0.41) | HDAC6HDAC1LTA4H | |
| SCHEMBL7172604 | 0.76 | HDAC6 (0.43) | HDAC6HDAC1LTA4H | |
| SCHEMBL27626492 | 0.74 | HDAC6 (0.39) | HDAC6HDAC1LTA4H | |
| Pyrrole SCHEMBL27626493 | 0.74 | HDAC6 (0.40) | HDAC6HDAC1LTA4H | |
| SCHEMBL19924632 | 0.72 | ASAH1 (0.45) | HDAC6HDAC1 | |
| SCHEMBL3646046 | 0.71 | FDPS (0.44) | HDAC6HDAC1LTA4HPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641904-A | The sulphur imido acyl group purine ketone compound that 7- for treating and preventing virus infection replaces | 豪夫迈·罗氏有限公司 | 2019-04-16 | — | — | CN | claimed |
| CN-109715214-A | Combination therapy of a TLR7 agonist and an HBV capsid assembly inhibitor | 豪夫迈·罗氏有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109641904-A | The sulphur imido acyl group purine ketone compound that 7- for treating and preventing virus infection replaces | 豪夫迈·罗氏有限公司 | 2019-04-16 | — | — | CN | disclosed |
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| CN-101405408-A | Method for enhancing lymphatic function | GEN HOSPITAL CORP (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | HDAC6 1082/4885HDAC1 1208/4885LTA4H 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.